Asahi Kasei (3407) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
6 Jun, 2025Executive summary
Operating income for FY 2024 reached ¥211.9 billion, up 50.6% year-over-year, marking a record high for the first time in six years, with all segments contributing to growth.
Net income attributable to owners of the parent surged 208.2% to ¥135.0 billion, driven by improved segment performance and absence of prior-year impairment losses.
FY 2025 aims for a new record in operating income (¥215.0 billion, +1.5% YoY), despite anticipated headwinds from foreign exchange and petrochemical market prices.
Announced "Trailblaze Together" medium-term management plan for FY 2025-2027, focusing on First Priority businesses and cost reductions.
Net sales rose 9.1% year-over-year to ¥3,037.3 billion, with all segments contributing to growth.
Financial highlights
FY 2024 net sales rose 9.1% year-over-year to ¥3,037.3 billion, in line with forecasts.
Operating income exceeded forecasts, up 50.6% to ¥211.9 billion; operating margin improved to 7.0%.
EBITDA increased 23.3% to ¥398.0 billion; EBITDA margin rose to 13.1%.
EPS grew 209.9% to ¥97.94; net income beat forecast by 22.7%.
Gross profit margin improved, with gross profit at ¥958.3 billion versus ¥816.0 billion the prior year.
Outlook and guidance
FY 2025 net sales forecasted at ¥3,117.0 billion (+2.6% YoY); operating income at ¥215.0 billion (+1.5% YoY).
Net income expected to decrease 7.4% to ¥125.0 billion due to structural transformation costs.
Dividend per share to rise to ¥40 in FY 2025 (+¥2 YoY); share repurchase of ¥30.0 billion completed in November 2024.
Q1–Q2 FY 2025 guidance anticipates a 12.8% decline in operating income and a 30.3% drop in net income year-over-year.
FY 2025 guidance incorporates risks from U.S. tariff policy and economic uncertainty, with a focus on First Priority business growth.
Latest events from Asahi Kasei
- Aicuris acquisition secures a robust infectious disease pipeline, accelerating pharma growth.3407
Acquisition presentation26 Feb 2026 - Record operating income and net income growth, with an upwardly revised full-year forecast.3407
Q3 20264 Feb 2026 - Net income up 10% YoY, full-year profit guidance raised, and dividend maintained.3407
Q2 20265 Nov 2025 - Operating income rose but net income plunged on one-time and extraordinary losses; outlook and dividends improved.3407
Q1 202631 Jul 2025 - Operating and net income surged, but currency losses drove comprehensive income negative.3407
Q2 202513 Jun 2025 - Operating income jumped 128.9% YoY in Q1, with a strong outlook for FY2024.3407
Q1 202513 Jun 2025 - Profits and sales surged, forecasts raised, and a large share buyback was completed.3407
Q3 20255 Jun 2025